CareDx, Inc
CDNA
Classificação em ações
#4635
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Preço da ação
$63.44
Última sincronização: 2026-10-16
Valor de mercado
$3.28B
Variação (1 dia)
-4.85%
Variação (1 ano)
340.25%
País
US
Negociar CareDx, Inc (CDNA)
Categoria
Healthcare
Margem Operacional de CareDx, Inc (CDNA)
Margem Operacional em October 2026 TTM: -0.92%
De acordo com os relatórios financeiros mais recentes e o preço das ações da CareDx, Inc, a margem operacional atual (TTM) é -0.92%. No final de 2023, a margem operacional era -72.55%.
Histórico da Margem Operacional da CareDx, Inc de 2012 a 2026
Margem Operacional no final de cada ano
| Ano | Margem Operacional | Alterar |
|---|---|---|
| 2026 (TTM) | -0.92% | -107.53% |
| 2024 | 12.21% | -116.83% |
| 2023 | -72.55% | 202.29% |
| 2022 | -24.00% | 139.28% |
| 2021 | -10.03% | 8.79% |
| 2020 | -9.22% | -52.25% |
| 2019 | -19.31% | -5.11% |
| 2018 | -20.35% | -51.55% |
| 2017 | -42.00% | -54.29% |
| 2016 | -91.88% | 116.70% |
| 2015 | -42.40% | -1,025.76% |
| 2014 | 4.58% | -218.04% |
| 2013 | -3.88% | -66.11% |
| 2012 | -11.45% | 0.00% |
Margem Operacional de empresas semelhantes ou concorrentes
| Empresa | Margem Operacional | Diferença na Margem Operacional | País |
|---|---|---|---|
| 17.97% | -119.53% |
US
|
|
| 20.42% | -122.20% |
US
|
|
| -10.70% | -88.37% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -124.16% |
US
|
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.